Modulation of IL-33/ST2 signaling as a potential new therapeutic target for cardiovascular diseases

IF 9.3 2区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Cytokine & Growth Factor Reviews Pub Date : 2023-06-01 DOI:10.1016/j.cytogfr.2023.06.003

Punniyakoti Veeraveedu Thanikachalam , Srinivasan Ramamurthy , Poojitha Mallapu , Sudhir Rama Varma , Jayaraj Narayanan , Mohammed AS Abourehab , Prashant Kesharwani

{"title":"Modulation of IL-33/ST2 signaling as a potential new therapeutic target for cardiovascular diseases","authors":"Punniyakoti Veeraveedu Thanikachalam , Srinivasan Ramamurthy , Poojitha Mallapu , Sudhir Rama Varma , Jayaraj Narayanan , Mohammed AS Abourehab , Prashant Kesharwani","doi":"10.1016/j.cytogfr.2023.06.003","DOIUrl":null,"url":null,"abstract":"<div>IL-33 belongs to the IL-1 family of cytokines, which function as inducers of Th2 cytokine production by binding with ST2L and IL-1RAcP. This, in turn, activates various signaling pathways, including the mitogen-activated protein kinase (MAPK), the inhibitor of Kappa-B kinase (IKK) pathway, and the phospholipase D-sphingosine kinase pathway. IL-33 has demonstrated protective effects against various cardiovascular diseases (CVDs) by inducing Th2 cytokines and promoting alternative activating M2 polarization. However, the soluble decoy form of ST2 (sST2) mitigates the biological effects of IL-33, exacerbating CVDs. Furthermore, IL-33 also plays a significant role in the development of asthma, arthritis, atopic dermatitis, and anaphylaxis through the activation of Th2 cells and mast cells. In this review, we aim to demonstrate the protective role of IL-33 against CVDs from 2005 to the present and explore the potential of serum soluble ST2 (sST2) as a diagnostic biomarker for CVDs. Therefore, IL-33 holds promise as a potential therapeutic target for the treatment of CVDs.</div>","PeriodicalId":11132,"journal":{"name":"Cytokine & Growth Factor Reviews","volume":"71 ","pages":"Pages 94-104"},"PeriodicalIF":9.3000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cytokine & Growth Factor Reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1359610123000266","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 2

Abstract

IL-33 belongs to the IL-1 family of cytokines, which function as inducers of Th2 cytokine production by binding with ST2L and IL-1RAcP. This, in turn, activates various signaling pathways, including the mitogen-activated protein kinase (MAPK), the inhibitor of Kappa-B kinase (IKK) pathway, and the phospholipase D-sphingosine kinase pathway. IL-33 has demonstrated protective effects against various cardiovascular diseases (CVDs) by inducing Th2 cytokines and promoting alternative activating M2 polarization. However, the soluble decoy form of ST2 (sST2) mitigates the biological effects of IL-33, exacerbating CVDs. Furthermore, IL-33 also plays a significant role in the development of asthma, arthritis, atopic dermatitis, and anaphylaxis through the activation of Th2 cells and mast cells. In this review, we aim to demonstrate the protective role of IL-33 against CVDs from 2005 to the present and explore the potential of serum soluble ST2 (sST2) as a diagnostic biomarker for CVDs. Therefore, IL-33 holds promise as a potential therapeutic target for the treatment of CVDs.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

调节IL-33/ST2信号作为心血管疾病潜在的新治疗靶点

IL-33属于IL-1细胞因子家族，其通过与ST2L和IL-1RAcP结合而发挥Th2细胞因子产生的诱导剂的作用。这反过来激活了各种信号通路，包括丝裂原活化蛋白激酶（MAPK）、Kappa-B激酶抑制剂（IKK）通路和磷脂酶D-鞘氨醇激酶通路。IL-33通过诱导Th2细胞因子和促进选择性激活M2极化，对各种心血管疾病（CVD）具有保护作用。然而，ST2的可溶性诱饵形式（sST2）减轻了IL-33的生物学效应，加剧了CVD。此外，IL-33还通过激活Th2细胞和肥大细胞在哮喘、关节炎、特应性皮炎和过敏反应的发展中发挥重要作用。在这篇综述中，我们旨在证明从2005年到现在IL-33对心血管疾病的保护作用，并探索血清可溶性ST2（sST2）作为心血管疾病诊断生物标志物的潜力。因此，IL-33有望成为治疗心血管疾病的潜在治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cytokine & Growth Factor Reviews 生物-生化与分子生物学

CiteScore

21.10

自引率

1.50%

发文量

审稿时长

22 days

期刊介绍： Cytokine & Growth Factor Reviews is a leading publication that focuses on the dynamic fields of growth factor and cytokine research. Our journal offers a platform for authors to disseminate thought-provoking articles such as critical reviews, state-of-the-art reviews, letters to the editor, and meeting reviews. We aim to cover important breakthroughs in these rapidly evolving areas, providing valuable insights into the multidisciplinary significance of cytokines and growth factors. Our journal spans various domains including signal transduction, cell growth and differentiation, embryonic development, immunology, tumorigenesis, and clinical medicine. By publishing cutting-edge research and analysis, we aim to influence the way researchers and experts perceive and understand growth factors and cytokines. We encourage novel expressions of ideas and innovative approaches to organizing content, fostering a stimulating environment for knowledge exchange and scientific advancement.

期刊最新文献

Cholecystokinin and gastrin as immune modulating hormones: Implications and applications. JAK inhibitors in immune regulation and treatment of vitiligo. I don't know about you, but I'm feeling IL-22. Glioblastoma-associated macrophages: A key target in overcoming glioblastoma therapeutic resistance. The role of transforming growth factor β in cervical carcinogenesis.